Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Julphar
Queensland Health
Cantor Fitzgerald
Teva
Covington
Chubb
US Army
Boehringer Ingelheim
Baxter

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207931

« Back to Dashboard

NDA 207931 describes TECHNIVIE, which is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug. Additional details are available on the TECHNIVIE profile page.

The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.
Summary for 207931
Tradename:TECHNIVIE
Applicant:Abbvie Inc
Ingredient:ombitasvir; paritaprevir; ritonavir
Patents:12
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 207931
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931 NDA AbbVie Inc. 0074-3082 0074-3082-28 4 CARTON in 1 CARTON (0074-3082-28) > 7 DOSE PACK in 1 CARTON > 1 KIT in 1 DOSE PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength12.5MG;75MG;50MG
Approval Date:Jul 24, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 24, 2018
Regulatory Exclusivity Use:
Regulatory Exclusivity Expiration:Dec 19, 2019
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Jul 24, 2018
Regulatory Exclusivity Use:NEW PRODUCT

Expired US Patents for NDA 207931

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 ➤ Subscribe ➤ Subscribe
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Citi
Julphar
Fuji
Fish and Richardson
US Army
Teva
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot